Table 1.
Baseline characteristics of randomized study participants
| Characteristic | ASAQ | AL | p valuea |
| n = 123 | n = 123 | ||
| Patients, n (percentage) | |||
| Agogo site | 41 (33.3%) | 39 (31.7%) | 0.785 |
| Agona site | 82 (66.7%) | 84 (68.3%) | |
| Sex (male: female), n | 68: 55 | 65: 58 | 0.701 |
| Age, months (SD) | 32.1 (± 16.1) | 30.7 (± 13.7) | 0.458 |
| Weight-for-ageb, z-score (SD) | -0.93 (± 1.2) | -0.81 (± 1.1) | 0.414 |
| Axillary temperature,°C (SD) | 38.1 (± 0.98) | 38.0 (± 1.1) | 0.891 |
| Parasite densityc,/μl | 38864 | 34255 | 0.572 |
| Haemoglobin, g/dl (SD) | 9.9 (± 1.9) | 9.6 (± 1.7) | 0.133 |
Please note:
Data are mean values (SD), unless otherwise indicated.
a Determined using Wilcoxon test or χ2 test. None of the parameters in both study arms was significantly different.
b According to the WHO child growth standards. http://www.who.int/childgrowth/standards/weight_for_age/en/index.html
c Geometric mean; parasite densities were determined from Giemsa-stained thick blood films.
ASAQ, artesunate plus amodiaquine; AL, artemether-lumefantrine
SD, standard deviation